# The importance of bone marrow biopsy for chronic myeloid leukemia classification—a case report

**Authors:** Natália Vital Gonçalves, Herton Luiz Alves Sales Filho, João Paulo Cabral de Magalhães Gomes, Guilherme Brasil Duffles Amarante, Gislaine Borba de Oliveira, Irene Lorand-Metze, Kátia Borgia Barbosa Pagnano, Guilherme Rossi Assis-Mendonça

PMC · DOI: 10.1007/s12308-026-00684-8 · Journal of Hematopathology · 2026-02-26

## TL;DR

A case report shows how bone marrow biopsy helped correctly diagnose a complex form of chronic myeloid leukemia.

## Contribution

The report emphasizes the critical role of bone marrow biopsy in identifying rare diagnostic patterns in CML.

## Key findings

- Bone marrow biopsy revealed lymphoid blast crisis in a patient suspected of having CML in chronic phase.
- Flow cytometry detected a small percentage of lymphoblasts, confirming the blast crisis diagnosis.
- The case highlights the necessity of combining multiple diagnostic techniques for accurate CML classification.

## Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR::ABL1 rearrangement, usually diagnosed by data of peripheral blood, bone marrow cytology, cytogenetics, and the detection of the BCR:ABL1 rearrangement. An accurate diagnosis, including the precise phase of the disease, is essential to guide appropriate treatment. We present the case of a patient admitted at our Institution with the hypothesis of CML in chronic phase, based on clinical and bone marrow cytological findings. Bone marrow biopsy showed some areas with morphologic features of CML in chronic phase but also sheets of B lymphoblasts, compatible with lymphoid blast crisis. Flow cytometry detected 1.18% of lymphoblasts. This report clearly illustrates the importance of the examination of bone marrow by several techniques. It highlights the importance of the biopsy in recognizing anomalous immunomorphological patterns, which can lead to diagnostic and therapeutic changes in CML.

## Linked entities

- **Diseases:** Chronic myeloid leukemia (MONDO:0011996)

## Full-text entities

- **Genes:** CD22 (CD22 molecule) [NCBI Gene 933] {aka SIGLEC-2, SIGLEC2}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CD33 (CD33 molecule) [NCBI Gene 945] {aka CD33rSiglec, SIGLEC-3, SIGLEC3, p67}, PAX5 (paired box 5) [NCBI Gene 5079] {aka ALL3, BSAP, PAX-5}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) [NCBI Gene 25] {aka ABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL}, MPO (myeloperoxidase) [NCBI Gene 4353], KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, IKZF1 (IKAROS family zinc finger 1) [NCBI Gene 10320] {aka CVID13, Hs.54452, IK1, IKAROS, LYF1, LyF-1}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, CD34 (CD34 molecule) [NCBI Gene 947], PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, DNTT (DNA nucleotidylexotransferase) [NCBI Gene 1791] {aka TDT}
- **Diseases:** positive (MESH:D000377), bruises (MESH:D003288), Ph (MESH:D010677), asthenia (MESH:D001247), septic shock (MESH:D012772), leukemias (MESH:D007938), extramedullary tumors (MESH:D023981), nosocomial infection (MESH:D003428), leukocytosis (MESH:D007964), transformation (MESH:D002472), ALL (MESH:D054198), crises (MESH:D013224), pain (MESH:D010146), CML (MESH:D015464), MPN (MESH:D009369), BP (MESH:D001752)
- **Chemicals:** prednisolone (MESH:D011239), imatinib (MESH:D000068877), vincristine (MESH:D014750)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946378/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946378/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946378/full.md

---
Source: https://tomesphere.com/paper/PMC12946378